ID

23073

Beschrijving

Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00395915

Link

https://clinicaltrials.gov/show/NCT00395915

Trefwoorden

Versies (1)
  1. 22-06-17 22-06-17 -
Geüploaded op

22 juni 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Schizophrenia NCT00395915

Engels

Eligibility Schizophrenia NCT00395915

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. current treatment with clozapine for the primary indication of schizophrenia (clinical diagnosis, guided by dsm-iv criteria).
Beschrijving

Clozapine | Schizophrenia

Datatype

boolean

Alias
UMLS CUI [1]
C0009079
UMLS CUI [2]
C0036341
2. treatment with clozapine for at least six months at a stable dose of 400 mg or more per day, unless the size of the dose was limited by side-effects.
Beschrijving

Clozapine | Dose Stable U/day | Dose Limited caused by Adverse effects

Datatype

boolean

Alias
UMLS CUI [1]
C0009079
UMLS CUI [2,1]
C0178602
UMLS CUI [2,2]
C0205360
UMLS CUI [2,3]
C0456683
UMLS CUI [3,1]
C0178602
UMLS CUI [3,2]
C0439801
UMLS CUI [3,3]
C0015127
UMLS CUI [3,4]
C0879626
3. unsatisfactory benefit from clozapine treatment, as indicated by the presence of positive symptoms (delusions, hallucinations, abnormal behaviour, clinical diagnosis)
Beschrijving

Clozapine Benefit Unsatisfactory | Symptoms Positive Present | Delusions | Hallucinations | Abnormal behavior | Diagnosis, clinical

Datatype

boolean

Alias
UMLS CUI [1,1]
C0009079
UMLS CUI [1,2]
C0814225
UMLS CUI [1,3]
C0439856
UMLS CUI [2,1]
C1457887
UMLS CUI [2,2]
C1514241
UMLS CUI [2,3]
C0150312
UMLS CUI [3]
C0011253
UMLS CUI [4]
C0018524
UMLS CUI [5]
C0233514
UMLS CUI [6]
C0332140
4. age 18 and above.
Beschrijving

Age

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
5. agreement between investigator and patient to enter the study.
Beschrijving

Study Subject Participation Status Agreement Investigator

Datatype

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C4255373
UMLS CUI [1,3]
C0035173
6. the patient is normally resident in italy.
Beschrijving

Residence

Datatype

boolean

Alias
UMLS CUI [1]
C0237096
7. it is considered clinically reasonable to try combination treatment with clozapine and aripiprazole or with clozapine and haloperidol.
Beschrijving

Combined Modality Therapy | Clozapine | aripiprazole | Haloperidol

Datatype

boolean

Alias
UMLS CUI [1]
C0009429
UMLS CUI [2]
C0009079
UMLS CUI [3]
C0299792
UMLS CUI [4]
C0018546
8. uncertainty about which trial treatment would be best for the participant.
Beschrijving

Therapeutic procedure Uncertain

Datatype

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0087130
9. no medical disorder or condition contraindicates either of the investigational drugs.
Beschrijving

Investigational New Drugs Medical contraindication Absent

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C1301624
UMLS CUI [1,3]
C0332197
10. agreement between investigator and patient to discontinue any antipsychotic drugs other than clozapine (including long-acting antipsychotic drugs).
Beschrijving

Antipsychotic Agents To be stopped | Antipsychotic Agents Active Long-term To be stopped | Clozapine Excluded

Datatype

boolean

Alias
UMLS CUI [1,1]
C0040615
UMLS CUI [1,2]
C1272691
UMLS CUI [2,1]
C0040615
UMLS CUI [2,2]
C0205177
UMLS CUI [2,3]
C0443252
UMLS CUI [2,4]
C1272691
UMLS CUI [3,1]
C0009079
UMLS CUI [3,2]
C2828389
Terug naar het begin van de pagina

Similar models

Eligibility Schizophrenia NCT00395915

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Clozapine | Schizophrenia
Item
1. current treatment with clozapine for the primary indication of schizophrenia (clinical diagnosis, guided by dsm-iv criteria).
boolean
C0009079 (UMLS CUI [1])
C0036341 (UMLS CUI [2])
Clozapine | Dose Stable U/day | Dose Limited caused by Adverse effects
Item
2. treatment with clozapine for at least six months at a stable dose of 400 mg or more per day, unless the size of the dose was limited by side-effects.
boolean
C0009079 (UMLS CUI [1])
C0178602 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
C0456683 (UMLS CUI [2,3])
C0178602 (UMLS CUI [3,1])
C0439801 (UMLS CUI [3,2])
C0015127 (UMLS CUI [3,3])
C0879626 (UMLS CUI [3,4])
Clozapine Benefit Unsatisfactory | Symptoms Positive Present | Delusions | Hallucinations | Abnormal behavior | Diagnosis, clinical
Item
3. unsatisfactory benefit from clozapine treatment, as indicated by the presence of positive symptoms (delusions, hallucinations, abnormal behaviour, clinical diagnosis)
boolean
C0009079 (UMLS CUI [1,1])
C0814225 (UMLS CUI [1,2])
C0439856 (UMLS CUI [1,3])
C1457887 (UMLS CUI [2,1])
C1514241 (UMLS CUI [2,2])
C0150312 (UMLS CUI [2,3])
C0011253 (UMLS CUI [3])
C0018524 (UMLS CUI [4])
C0233514 (UMLS CUI [5])
C0332140 (UMLS CUI [6])
Age
Item
4. age 18 and above.
boolean
C0001779 (UMLS CUI [1])
Study Subject Participation Status Agreement Investigator
Item
5. agreement between investigator and patient to enter the study.
boolean
C2348568 (UMLS CUI [1,1])
C4255373 (UMLS CUI [1,2])
C0035173 (UMLS CUI [1,3])
Residence
Item
6. the patient is normally resident in italy.
boolean
C0237096 (UMLS CUI [1])
Combined Modality Therapy | Clozapine | aripiprazole | Haloperidol
Item
7. it is considered clinically reasonable to try combination treatment with clozapine and aripiprazole or with clozapine and haloperidol.
boolean
C0009429 (UMLS CUI [1])
C0009079 (UMLS CUI [2])
C0299792 (UMLS CUI [3])
C0018546 (UMLS CUI [4])
Therapeutic procedure Uncertain
Item
8. uncertainty about which trial treatment would be best for the participant.
boolean
C0087111 (UMLS CUI [1,1])
C0087130 (UMLS CUI [1,2])
Investigational New Drugs Medical contraindication Absent
Item
9. no medical disorder or condition contraindicates either of the investigational drugs.
boolean
C0013230 (UMLS CUI [1,1])
C1301624 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
Antipsychotic Agents To be stopped | Antipsychotic Agents Active Long-term To be stopped | Clozapine Excluded
Item
10. agreement between investigator and patient to discontinue any antipsychotic drugs other than clozapine (including long-acting antipsychotic drugs).
boolean
C0040615 (UMLS CUI [1,1])
C1272691 (UMLS CUI [1,2])
C0040615 (UMLS CUI [2,1])
C0205177 (UMLS CUI [2,2])
C0443252 (UMLS CUI [2,3])
C1272691 (UMLS CUI [2,4])
C0009079 (UMLS CUI [3,1])
C2828389 (UMLS CUI [3,2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial